Biocon Share Price Surges: Why Q3 Profit Jumped 475% to ₹144 Crore

Synopsis: Biocon Limited (NSE: BIOCON) reported a staggering 475% YoY surge in consolidated net profit to ₹144 Crore for Q3 FY26, supported by a 9% rise in operating revenue to ₹4,173 Crore. The sharp turnaround was driven by robust momentum in the Generics segment and the full integration of Biocon Biologics as a wholly-owned subsidiary. Investors are cheering the strengthened balance sheet and a projected ₹300 Crore annual interest cost saving starting FY27.

On February 13, 2026, shares of Biocon Limited opened strong at ₹374 and touched an intraday high of ₹381.30 on the NSE, as investors reacted to a “high-quality” earnings turnaround. While the broader market faced headwinds, Biocon’s reported net profit of ₹144 Crore—up from just ₹25 Crore in the previous year—signaled the successful culmination of its massive strategic restructuring. The company’s move to acquire the remaining 2% stake in Biocon Biologics has officially set the stage for its “One Biocon” vision.

The Bengaluru-based biotech major is now seeing the fruits of its $1 Billion equity raise through two QIPs. By retiring structured debt and settling minority interests, management has significantly de-risked the balance sheet, leading to credit rating upgrades from S&P (BB+ Stable) and Fitch (Positive).

---

Why is Biocon stock rising today?

The primary driver is the explosive growth in the Generics division, which saw revenue skyrocket 24% YoY to ₹851 Crore. This was fueled by the “first-to-market” direct launches of gLiraglutide (diabetes and obesity treatment) across European markets like the Netherlands. This high-margin push into GLP-1 analogues is being viewed as a massive long-term growth engine by Dalal Street.

Additionally, Biocon Biologics continues to be the heavy lifter, contributing ₹2,497 Crore (up 9%) to the topline. The biosimilars arm saw its EBITDA grow by 44% to ₹700 Crore, as economies of scale and better pricing in North America boosted margins to 28%. The market is pricing in a cleaner P&L for FY27, as interest costs are expected to drop by ₹300 Crore annually following the recent debt settlements.

Biocon Q3 FY26 Financial Snapshot (Consolidated)

Key Metric	Q3 FY26 (Actual)	Q3 FY25 (YoY)	Growth (%)
Operating Revenue	₹4,173 Cr	₹3,821 Cr	9.1% ↑
EBITDA	₹951 Cr	₹787 Cr	20.8% ↑
Reported Net Profit	₹144 Cr	₹25 Cr	475% ↑

---

The “Analyst Consensus” on Biocon

Institutional analysts are re-rating the stock as it shifts from a “capital-heavy integration phase” to a “free cash flow generation phase.”

• Generics Momentum: Analysts note that the gLiraglutide rollout in the EU is just the beginning, with US approvals expected to be the next major catalyst.
• Syngene Recovery: While the CRDMO segment (Syngene) saw a minor 3% revenue dip, experts believe the extension of the Bristol Myers Squibb partnership until 2035 provides a solid long-term floor.
• Technical Outlook: Chartists highlight that the stock has found strong support at ₹365 and is eyeing a move toward ₹410 if it sustains above the 200-day EMA.

Also Read: GE Power India Share Price Hits 20% Upper Circuit: Why Q3 Profits Surged 123%

---

The Bottom Line

Biocon’s 475% profit jump is a definitive sign that the company has finally simplified its complex corporate structure. For the Aam Aadmi investor, the focus remains on the ₹300 Crore debt-saving tailwind and the company’s aggressive expansion into the multi-billion dollar weight-loss drug market.